Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
Terry Kim,1 Kenneth Sall,2 Edward J Holland,3 R Kim Brazzell,4 Susan Coultas,4 Preeya K Gupta1 1Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA; 2Sall Research Medical Center, Inc, Artesia, CA, USA; 3Department of Ophthalmology, Cincinnati Eye Institute, University of Cinci...
Enregistré dans:
Auteurs principaux: | Kim T, Sall K, Holland EJ, Brazzell RK, Coultas S, Gupta PK |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/85e137a6ee1d4a6aa393eb7e8b46a830 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
par: Fong R, et autres
Publié: (2019) -
Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
par: Sheppard JD, et autres
Publié: (2019) -
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
par: Khaimi MA
Publié: (2018) -
Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains
par: Ebrahimiadib N, et autres
Publié: (2020) -
Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
par: Brooks CC, et autres
Publié: (2020)